The Therapeutic Goods Administration (TGA) has provisionally approved a booster dose of the Pfizer Australia Pty Ltd COVID-19 vaccine, COMIRNATY, for individuals 18 years and older.
The provisional approval means that individuals aged 18 years and older may receive a booster (third dose), at least six months after the completion of a COVID-19 vaccine primary series. This primary series can be of any of the COVID-19 vaccines registered for use in Australia, although data on the use of COMIRNATY as a booster with other COVID-19 vaccines is more limited.
Individuals who have received one dose of COMIRNATY should preferably receive a second dose of COMIRNATY to complete the primary vaccination course and for any additional doses.
Further advice on the use of boosters will be provided to government shortly by the Australian Technical Advisory Group on Immunisation (ATAGI).
In addition, consistent with ATAGI advice, the TGA Product Information (PI) also now includes a statement that a third dose may be given to severely immunocompromised people aged 12 years and over at least 28 days after the second dose.
